Joshua K. Sabari, MD

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.

Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.

New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.

Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.